Preliminary results from a study of remdesivir: an antiviral medication show that it can help hospital patients with COVID-19.
The National institute sponsor the study of Allergy and infective Diseases, which Fauci leads, and which is part of the NIH.
On February 21 The NIH antiviral trial was started, conducted by Gilead Sciences, The preliminary study final result* are not yet published in a peer-reviewed trial but NIH released them after an analysis by the data safety monitoring board overseeing the trial. Fauci said the results were announced because of the ethical responsibility to allow the placebo group to access remdesivir, since there was now clear evidence that the drug works.
The analytic thinking found that remdesivir shortened the time it took a hospitalized COVID-19 patient to recover, likened to a placebo. The study defined as being well enough to be discharged from the hospital or returning to normal activity.
The preliminary resultants found that patients who received remdesivir recovered 31% faster — the median value time to recovery was 11 days rather than 15 days. The results also suggest a slightly lower death rate rate for the group receiving remdesivir, but until all over data is analyzed it is not certain if that effect is important.
Fauci said that while 31% may not seem like a huge deal, It is a very important proof of concept. Because what it has proven is that a drug can block this virus.§double§
The results will be sent to a journal for referee.
Doctor. Evelyn Ling, is a professor of medicine and is involved with the remdesivir trial at Stanford University.
§double§It§apostrofe§s definitely very promising and very exciting that we might have this option to treat these patients who currently don§apostrofe§t have any great options right now, she says. Every day you are in ICU, that is a lot of stress on the body, that is a lot of recovery time needed. So I think if you could shorten that, I think that§apostrofe§s great for our patients.
Doc. Aneesh K. Mehta, an investigator at the remdesivir trial site at Emory University, was optimistic about the drug is potential, based on the preliminary data. We believe that remdesivir is the first medication to display a positive effect on patients with COVID-19, he said at a press conference.
He also offered some caveats.
1st, he underlined that this is preliminary experimental on about half the patients in the trial, and it has not undergone the robust analysis that will be conducted by the statisticians and the scientists at the NIH in the coming weeks.
And while the preliminary data showed no serious side effects of remdesivir, we still do not have all the safety data reported from the NIH, and that will be critically important to understanding how we use this medicine in the future, he said.
Mehta also noted that remdesivir is it a cure-all.
It is very important to understand that remdesivir and antivirals in general are not silver bullets, he said. They do not directly get rid of an infection. They work by slowly preventing the virus from making more of itself.
Patients still need other care to support their recovery, he said, especially if the inflammation that can be associate with COVID-19 has already damaged their organs.
Fauci told that new studies will examine combining remdesivir with a different drugs, such as an anti-inflammatory drug, to see how those compare to using remdesivir alone.
Gilead Sciences also announced on Wednesday that a trial run had found that patients receiving a 10-day treatment course of remdesivir achieved similar improvement in clinical status compared with those taking a 5-day treatment.
The study demonstrates the potential for some patients to be treated with a 5-day regimen, which could significantly expand the number of patients who could be treated with our current supply of remdesivir, doc. Merdad Parsey, chief medical officer of Gilead Sciences, said in a statement.
Preliminary results from a study of remdesivir: an antiviral medication show that it can help hospital patients with COVID-19. The National institute